colorectal cancer

FDA Lifts Clinical Hold on KEYNOTE-B79 Trial of a Novel CAR T-Cell Agent in mCRC

The CYAD-101-002 trial may resume after the FDA lifted the partial clinical hold to evaluate risk to study patients with metastatic colorectal cancer. The FDA has lifted the clinical hold on the phase 1b CYAD-101-002 trial (KEYNOTE-B79; NCT04991948), which is evaluating the safety and clinical activity of the investigational chimeric antigen receptor (CAR T)-cell therapy …

FDA Lifts Clinical Hold on KEYNOTE-B79 Trial of a Novel CAR T-Cell Agent in mCRC Read More »

FDA Lifts Clinical Hold on KEYNOTE-B79 Trial Evaluating CAR T-cell Therapy CYAD-101 in Metastatic CRC

The FDA has lifted a clinical hold on the phase 1b KEYNOTE-B79 trial, which is evaluating the safety and clinical activity of CYAD-101 given concurrently with FOLFOX and followed by pembrolizumab in patients with unresectable metastatic colorectal cancer. The FDA has lifted a clinical hold on the phase 1b CYAD-101-002 trial (KEYNOTE-B79; NCT04991948), which is …

FDA Lifts Clinical Hold on KEYNOTE-B79 Trial Evaluating CAR T-cell Therapy CYAD-101 in Metastatic CRC Read More »